ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.

MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal ...

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markersFull analysis of Phase 2 ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

South Korean biosimilars developer Celltrion late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

Strictly Come Dancing star Amy Dowden said it was a "surreal" experience to be honoured by King Charles at Buckingham Palace.

Strictly’s Amy Dowden discussed chemotherapy with Charles as she was made an MBE The Welsh dancer was formally made an MBE at a ceremony ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...